List of Excipients in Branded Drug FAMOTIDINE 10 MG

Generic Drugs Containing FAMOTIDINE 10 MG

Company	Ingredient	NDC	Excipient
MARKSANS PHARMA LIMITED	famotidine 10 mg	25000-086	CARNAUBA WAX
MARKSANS PHARMA LIMITED	famotidine 10 mg	25000-086	FERRIC OXIDE RED
MARKSANS PHARMA LIMITED	famotidine 10 mg	25000-086	HYDROXYPROPYL CELLULOSE
MARKSANS PHARMA LIMITED	famotidine 10 mg	25000-086	HYPROMELLOSE
MARKSANS PHARMA LIMITED	famotidine 10 mg	25000-086	MAGNESIUM STEARATE
MARKSANS PHARMA LIMITED	famotidine 10 mg	25000-086	MICROCRYSTALLINE CELLULOSE 102
MARKSANS PHARMA LIMITED	famotidine 10 mg	25000-086	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in FAMOTIDINE 10 MG?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	FERRIC OXIDE RED
1	HYDROXYPROPYL CELLULOSE
1	HYPROMELLOSE
1	MAGNESIUM STEARATE
1	MICROCRYSTALLINE CELLULOSE 102
1	SILICON DIOXIDE

Famotidine 10 mg Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Famotidine 10 mg is a mature, low-cost H2-receptor antagonist with no meaningful molecule-level exclusivity in the U.S. The commercial opportunity is concentrated in OTC differentiation, dosage-form convenience, taste, clean-label positioning, manufacturing efficiency, and combination products. Excipient selection should support rapid disintegration, acceptable taste, chemical stability, low tablet weight, and broad consumer acceptability without creating unnecessary regulatory or supply-chain exposure.

What is the FDA regulatory status of famotidine 10 mg?

Famotidine is FDA-approved as an H2-receptor antagonist for reducing gastric acid and treating conditions including duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Prescription famotidine products commonly use 20 mg and 40 mg strengths. The 10 mg strength is primarily associated with OTC heartburn products.

OTC famotidine is marketed under the FDA nonprescription framework for acid reducers. Product labeling must comply with the applicable OTC monograph requirements, the Drug Facts rule, dosage restrictions, warnings, and active-ingredient specifications.[1,2]

Attribute	Famotidine 10 mg position
Therapeutic class	H2-receptor antagonist
Primary OTC use	Relief and prevention of heartburn
Common dosage form	Immediate-release tablet or chewable tablet
Prescription strengths	Commonly 20 mg and 40 mg
OTC strength	10 mg is widely marketed
U.S. approval history	Originator prescription products approved in the 1980s
Current molecule exclusivity	Expired
Biosimilar exposure	None; famotidine is a small molecule
Primary regulatory route	OTC monograph or ANDA/NDA, depending on product and claims
Orange Book relevance	More relevant to prescription products than OTC monograph products

Famotidine is not a biologic. Biosimilar competition is therefore irrelevant. Competitive pressure comes from generic tablets, OTC store brands, branded OTC products, chewables, antacid combinations, and alternative H2 blockers.

What patents protect famotidine 10 mg products?

Famotidine 10 mg has no commercially significant remaining composition-of-matter exclusivity in the United States. The original famotidine patent estate is historical rather than an active barrier to generic or private-label development.

The original U.S. famotidine patent is generally identified as U.S. Patent No. 4,496,737, assigned to Merck-related interests and directed to famotidine and related compounds. Its term expired long ago under the pre-1995 patent-term framework. Formulation and manufacturing patents associated with specific products may have existed, but they do not create broad exclusivity over famotidine 10 mg as an active ingredient.[3]

How many patents cover famotidine 10 mg?

For a new U.S. OTC famotidine 10 mg immediate-release product, the practical patent burden is low:

Patent category	Commercial relevance
Famotidine compound patent	Expired
Basic acid-reduction use	Not a practical exclusivity barrier
Standard immediate-release tablet	Generally design-around territory
Conventional chewable tablet	Usually vulnerable to independent formulation development
Brand-specific trade dress	Enforceable separately from patent rights
Proprietary taste-masking system	Potentially protectable if genuinely novel
Drug-device combination	Potentially protectable if the delivery system is novel
Manufacturing process	Relevant only if the process is difficult to design around

A company should conduct a current patent search before launch, but famotidine 10 mg is generally a freedom-to-operate exercise involving excipient combinations, process claims, trademarks, and trade dress rather than an active compound patent.

When does famotidine 10 mg lose exclusivity?

Famotidine lost effective U.S. molecule exclusivity decades ago. The originator’s commercial protection has been replaced by generic competition and OTC brand recognition.

Prescription famotidine products entered the generic market after expiration of the originator protection. OTC famotidine products are not typically protected by current Orange Book-listed patents in the same manner as an innovative prescription drug. OTC competition can proceed through monograph compliance without relying on an originator NDA’s remaining patent estate.

What is the Orange Book status of famotidine 10 mg?

The Orange Book primarily identifies approved prescription drug products and their patent and exclusivity information. OTC monograph products, including many famotidine 10 mg products, do not function as conventional Orange Book-listed branded prescription products.[4]

The commercial implication is important: a company evaluating a 10 mg OTC launch should not treat the absence of an Orange Book listing as proof that every formulation or trademark is free of third-party rights. The relevant review should cover:

• Current Orange Book entries for prescription famotidine products.
• FDA OTC monograph requirements.
• Product-specific formulation patents.
• Trademark registrations.
• Trade dress and packaging rights.
• Supplier restrictions for proprietary excipients.
• Any litigation involving a target brand or formulation.

What excipients are used in famotidine 10 mg tablets?

Famotidine 10 mg immediate-release tablets typically use a conventional excipient platform. Exact inactive ingredients vary by manufacturer and dosage form. Public product labels commonly identify combinations of diluents, binders, disintegrants, lubricants, glidants, coating materials, and colorants.[5]

A conventional tablet may include:

Excipient function	Typical options	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet weight and compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes rapid breakup after ingestion
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose	Protects the tablet and improves appearance
Plasticizer	Polyethylene glycol	Improves coating flexibility
Sweetener	Sucralose, aspartame, acesulfame potassium, sugar alcohols	Supports chewable or orally disintegrating products
Flavor	Mint, berry, citrus, or neutral flavors	Masks bitterness
Colorant	Approved iron oxides, lakes, or other permitted colorants	Supports product identification

Famotidine has a bitter pharmaceutical taste. Taste management is more important for chewable and orally disintegrating formats than for conventional film-coated tablets.

What excipient strategy is best for a famotidine 10 mg tablet?

The strongest baseline strategy is a low-weight, direct-compression or dry-granulated tablet using a rapid disintegrant and a neutral or low-sugar filler. The formulation should target fast disintegration without excessive friability or tablet capping.

Recommended immediate-release platform

A commercially practical platform would use:

1. Microcrystalline cellulose or mannitol as the primary filler.
2. Crospovidone or croscarmellose sodium as the principal disintegrant.
3. Low-level colloidal silicon dioxide for flow.
4. Magnesium stearate or sodium stearyl fumarate at the lowest effective concentration.
5. A thin film coat for appearance, swallowability, and moisture protection.

The formulation should avoid unnecessary complexity. Famotidine 10 mg is a low-dose product, so content uniformity, blend segregation, and low-dose assay variability are more important than maximizing active loading.

Direct compression versus wet granulation

Criterion	Direct compression	Wet granulation
Capital and processing cost	Lower	Higher
Number of processing steps	Fewer	More
Scale-up speed	Faster	Slower
Moisture exposure	Lower	Higher
Blend uniformity	Requires robust powder engineering	Often easier to control
Tablet hardness	Dependent on excipient platform	Often strong
Best use case	Stable, flowable formulation	Poor flow, segregation, or compression problems

Direct compression is usually preferable for a cost-sensitive OTC product if blend uniformity and tablet robustness meet specifications. Wet granulation may be justified where the selected excipient system produces poor flow, high segregation, or inadequate content uniformity.

What formulations are protected or commercially attractive for famotidine 10 mg?

The most attractive formulation opportunities are not conventional tablets alone. They are differentiated consumer formats that justify a higher price or improve adherence.

Chewable tablets

Chewable famotidine 10 mg products can compete on:

• Faster consumer use without water.
• Improved portability.
• Flavor and mouthfeel.
• Sugar-free or reduced-sugar claims.
• Smaller tablet size.
• Unit-dose blister packaging.

Chewables require a stronger taste-masking system than film-coated tablets. Mannitol is useful for cooling mouthfeel and lower hygroscopicity. Sorbitol can improve chewability but may create gastrointestinal tolerance issues at higher quantities. Sweeteners, flavors, and lubricants must be balanced to avoid a chalky or lingering aftertaste.

Orally disintegrating tablets

An orally disintegrating tablet can occupy a convenience niche, particularly for travel or nighttime use. The formulation must achieve rapid dispersion with low friability. Crospovidone, mannitol, and specialized co-processed excipients are common development choices.

The main risks are:

• Bitter taste exposure.
• Moisture sensitivity.
• Fragility during packaging and transport.
• Higher packaging cost.
• Consumer confusion with chewable products.

An orally disintegrating product should use high-barrier blister packaging unless stability data support bottles.

Low-sugar and sugar-free products

A sugar-free product can address diabetic, calorie-conscious, and dental-health segments. Polyols and high-intensity sweeteners provide flexibility, but the formulation must control cooling effects, hygroscopicity, laxation risk, and aftertaste.

A "sugar-free" claim requires formulation and labeling controls. The product should not rely on a sugar-free positioning if the excipient system creates an unpleasant mouthfeel or requires excessive sweetener loading.

Combination products

Famotidine 10 mg can be combined with antacids such as calcium carbonate and magnesium hydroxide for products that target both rapid symptom relief and longer acid suppression. Combination products can command stronger shelf positioning but create more regulatory and technical complexity.

Key development issues include:

• Chemical and physical compatibility.
• Increased tablet weight.
• Antacid taste and chalkiness.
• Mineral-related assay interference.
• Different dissolution behavior.
• More complex labeling and dosage instructions.
• Greater risk of infringing a branded combination product’s formulation rights.

A combination product is commercially more differentiated than plain famotidine, but it is not the lowest-risk entry route.

What manufacturing and IP barriers affect famotidine 10 mg?

Manufacturing barriers are manageable but not trivial. The main technical challenge is uniform distribution of 10 mg famotidine throughout the blend, especially in a low-dose tablet with a high proportion of excipients.

Manufacturing controls

Critical process variables include:

• Particle-size distribution of famotidine and filler.
• Pre-blending and geometric dilution.
• Blend time and lubricant addition time.
• Segregation during transfer and compression.
• Tablet hardness and friability.
• Disintegration and dissolution.
• Coating weight gain.
• Moisture exposure.
• Packaging line rejection rate.

A robust process should use in-process blend sampling and validated content-uniformity controls. Excessive lubrication can slow dissolution, while insufficient lubrication can cause sticking and tooling damage.

Excipient supply risk

The most important supply risks are not unique to famotidine. They relate to availability and grade consistency for:

• Microcrystalline cellulose.
• Crospovidone.
• Croscarmellose sodium.
• Mannitol.
• Film-coating systems.
• High-intensity sweeteners.
• Pharmaceutical-grade flavors.

A dual-source strategy is practical for standard excipients. Proprietary co-processed excipients may improve performance but can raise cost and create supplier dependence.

Which companies are challenging the famotidine 10 mg market?

Competition comes from several groups:

Competitor group	Competitive advantage
Branded OTC manufacturers	Consumer recognition and retail placement
Store-brand retailers	Low price and private-label shelf access
Generic pharmaceutical companies	Manufacturing scale and low cost
Antacid brands	Faster perceived relief
Proton-pump inhibitor brands	Longer duration of acid suppression
Combination-product marketers	Multi-symptom positioning
E-commerce private labels	Flexible packaging and direct consumer acquisition

The main commercial threat is not a new famotidine molecule. It is a retailer or contract manufacturer offering a lower-cost equivalent with better shelf placement, stronger packaging, or a more convenient format.

What generic entry risks exist for famotidine 10 mg?

Generic entry risk is high because the active ingredient is old, the clinical use is well established, and conventional formulations are straightforward. A new entrant should assume that a standard film-coated tablet will be rapidly copied.

Differentiation should therefore rely on a combination of:

• Distinct dosage form.
• Better taste.
• Lower tablet size.
• Sugar-free positioning.
• Improved blister portability.
• Nighttime or travel packaging.
• Two-count or seven-count trial packs.
• Retailer-specific packaging.
• Combination therapy.
• Stronger consumer instructions.

Marketing claims must remain within FDA requirements. A formulation cannot create unsupported claims such as "faster acting" or "longer lasting" without appropriate comparative evidence and compliant labeling.

How does famotidine 10 mg compare with competing acid reducers?

Product class	Main consumer proposition	Famotidine 10 mg position
Antacids	Fast neutralization of existing acid	Famotidine may offer longer suppression but slower perceived onset
H2 blockers	Acid reduction with relatively rapid onset	Direct competitive class
Proton-pump inhibitors	Longer acid suppression for frequent symptoms	Less suitable for immediate, occasional relief positioning
Famotidine-antacid combinations	Immediate and sustained positioning	Higher formulation and regulatory complexity
Calcium carbonate products	Low price and broad availability	Famotidine competes on mechanism and duration

Famotidine 10 mg is best positioned for occasional heartburn prevention or relief where consumers want an acid-reducing product without the complexity of a longer-course proton-pump inhibitor regimen.

What licensing deals and settlement agreements affect famotidine 10 mg?

No major current licensing structure is required to market a conventional famotidine 10 mg OTC product. The active ingredient is off-patent, and standard excipients are broadly available.

A licensing transaction may still be relevant for:

• Proprietary orally disintegrating technology.
• Taste-masking systems.
• Co-processed excipients.
• Fast-dissolution platforms.
• Unit-dose packaging systems.
• Branded private-label supply arrangements.
• Combination-product technology.

No settlement agreement should be assumed to control market entry without a product-specific litigation review. Because OTC products may fall outside the standard prescription Orange Book framework, trademark, trade dress, formulation, and contract rights may be more commercially relevant than Paragraph IV settlements.

What is the Paragraph IV risk for famotidine 10 mg?

Paragraph IV litigation is generally not the central launch issue for an OTC monograph famotidine 10 mg product. Paragraph IV certifications are associated with ANDA applications challenging listed patents for approved reference drugs. A conventional OTC monograph product may not involve the same pathway.

For prescription famotidine products, an ANDA applicant must evaluate any listed patents associated with the relevant reference product. Given the age of famotidine, the practical risk from active compound patents is low. Product-specific formulation claims remain the principal area requiring review.

How strong is the patent estate for famotidine 10 mg?

The patent estate is weak for the active ingredient and conventional tablet. It can become stronger for a genuinely differentiated delivery system.

Asset	Relative protection
Famotidine active ingredient	Very low
Standard 10 mg tablet	Low
Conventional film coating	Very low
Taste-masked chewable	Moderate if technically novel
Orally disintegrating system	Moderate
Proprietary combination product	Moderate, subject to claim scope
Packaging and dosing system	Moderate
Brand and trade dress	Potentially strong but non-patent

A patent strategy should focus on narrowly defined formulation or process claims supported by comparative data. Broad claims covering famotidine plus routine excipients are vulnerable to invalidity and design-around arguments.

What commercial opportunities exist for famotidine 10 mg?

The highest-probability opportunities are:

1. Private-label OTC supply for national and regional retailers.
2. Sugar-free chewable tablets.
3. Low-weight orally disintegrating tablets.
4. Travel blister packs.
5. Pediatric-oriented products only where labeling, dosing, and clinical justification support the intended use.
6. Famotidine-antacid combinations.
7. E-commerce multipacks and subscription packaging.
8. Contract manufacturing for branded OTC companies.
9. Export products adapted to local OTC regulations.
10. Premium packaging with unit-dose convenience.

Revenue exposure should be assessed through retail velocity, average selling price, retailer margin, and repeat purchase rather than through molecule-level exclusivity. Public sources generally do not isolate revenue for famotidine 10 mg by brand, dosage form, or retailer. A product forecast should therefore be built from channel assumptions and comparable OTC acid-reducer sales data rather than from patent duration.

Key Takeaways

• Famotidine 10 mg is an off-patent, highly competitive OTC opportunity.
• The active ingredient provides little or no defensible exclusivity.
• Immediate-release tablets have the lowest technical and regulatory risk but also the weakest differentiation.
• Chewable and orally disintegrating formats offer better commercial positioning.
• Taste masking, disintegration, tablet robustness, and low-dose content uniformity are the core formulation priorities.
• Combination products can create stronger consumer differentiation but increase regulatory and manufacturing complexity.
• Orange Book and Paragraph IV analysis is less central for OTC monograph products than formulation, trademark, trade dress, and labeling review.
• The strongest commercial model is likely a low-cost, high-volume private-label or differentiated convenience product.
• Manufacturing and excipient sourcing are manageable with standard pharmaceutical grades and dual-source planning.
• A new patent strategy should target a specific formulation, delivery system, process, or packaging advantage rather than famotidine itself.

FAQs About Famotidine 10 mg Excipient and Commercial Strategy

Is famotidine 10 mg suitable for a chewable tablet?

Yes. A chewable format is technically feasible and commercially differentiated, but it requires effective bitterness control, acceptable mouthfeel, low friability, and compliant sweetener and flavor selection.

What is the best filler for famotidine 10 mg tablets?

Microcrystalline cellulose is a practical filler for direct compression. Mannitol is more attractive for chewable and orally disintegrating products because it supports palatability and mouthfeel.

Can famotidine 10 mg be formulated without lactose?

Yes. Lactose-free formulations can use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or suitable co-processed excipients. The selected platform must still meet content-uniformity, dissolution, and mechanical-strength requirements.

Does famotidine 10 mg have biosimilar competition?

No. Famotidine is a small-molecule drug, so competition comes from generic and OTC products rather than biosimilars.

Is a famotidine 10 mg private-label product commercially viable?

Yes, particularly through retailer private-label, e-commerce, travel packs, sugar-free formats, and chewable products. A standard tablet can be manufactured at low cost, but premium economics require meaningful convenience, taste, packaging, or combination-product differentiation.

References

1. U.S. Food and Drug Administration. (2024). Drug facts label requirements for over-the-counter human drug products. https://www.fda.gov
2. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Parts 201, 331, and applicable OTC drug provisions. https://www.ecfr.gov
3. U.S. Patent and Trademark Office. (1985). U.S. Patent No. 4,496,737: Famotidine and related compounds. https://patents.google.com
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
5. National Library of Medicine. (2024). DailyMed: Famotidine and OTC famotidine product labeling. https://dailymed.nlm.nih.gov